Less obesity after craniopharyngeoma treatment thanks to centralization (Van Schaik et al., 2023) The number of children facing obesity after craniopharyngeoma treatment has decreased since the Princess Máxima Center opened in 2018.
Good results with new drug in low-grade glioma (Kilburn et al., 2023) The new drug tovorafenib (also known as DAY101) is well tolerated and inhibits tumor growth in a large proportion of children and young adults with low-grade glioma.
Higher risk of being overweight and hormone imbalances in children with a brain tumor (Van Schaik et al., 2021) Weight problems in children with a brain tumor may be related to a malfunctioning hormone balance, according to a large-scale long-term study.